Hays Personalized Medicine in Oncology

Precision Oncology and Transformative Technologies
Erscheinungsjahr 2026
ISBN: 978-3-032-14437-9
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 363 Seiten

Reihe: Medicine (R0)

This book covers the field of precision oncology and is aligned with the targeted therapy drug development paradigm. Chapters present the relevance of immunotherapies as important and pivotal treatment strategies for cancer. The book outlines how Immune checkpoint inhibitors, CAR T cell therapies, antibody drug conjugates and bispecific antibodies evolved through the conduct of clinical trials and the resulting data to become critical components of the oncologist’s armamentarium. The mechanism of each class is described in detail and how each has advantages and limitations concerning existing standards of care, demonstrating that they complement and contrast with each other; resistance mechanisms are also discussed. Targeted therapies for solid tumors and hematologic malignancies are explained in-depth. The roles of cancer genomics and liquid biopsy for precision oncology are also explored. 
 
This book sufficiently fills a gap by coalescing these studies into a thorough, yet clear compendium of these therapies. It describes the prognostic and predictive significance of each drug, biomarkers for determining their therapeutic potential, along with the assays (e.g., IHC) that evaluate them. 
 
Personalized Medicine in Oncology is a valuable resource for oncologists and clinicians as well as graduate medical students, cancer nurse practitioners, pharmacists, and clinicians in other related therapeutic areas of interest. 

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Hays, Priya

Inhaltsverzeichnis

Introduction: The Development of Precision Medicine.- Part I.-Targeted Therapies Solid Tumors.-Targeted Therapies Hematological malignancies .-Cancer Immunotherapies Parts 1 and 2.-Checkpoint Blockade.-Cellular Therapies.-Bispecific Antibodies.-Antibody Drug Conjugates.-Personalized Cancer Vaccines.-Combination Therapies.-Immunogenomics.-Part II.-Economic Evaluations of Precision Oncology.-Ethical Issues, Health Policy and Law .-Artificial Intelligence and Big Data in Oncology.-Public Health and Global Healthcare in Personalized Cancer.-Regulatory Frameworks.-Health Disparities.-Conclusion: Neoadjuvant and Adjuvant Care Settings.

Über Autor(innen)

Priya Hays Hays Documentation Specialists San Mateo, CA  USA  

Priya Hays, M.S., Ph.D. is an accomplished science writer, having written and published five books as well as having authored over thirty publications in journals as varied as the , , , and focusing on personalized medicine and precision oncology. She served as Guest Editor for a volume on cancer immunotherapies in the Cancer Treatment and Research series and wrote the second edition of her book on personalized medicine Advancing Healthcare Through Personalized Medicine, both published by Springer Nature.  Her sixth book is a compilation of her published and conference papers entitled “A Dialectical Mind: Essays in Literary Studies, Science and Medicine” published by Eliva Press. She is an elected member of the American Association for Cancer Research, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, the American College of Medical Genetics and Genomics, the American Association of Immunologists and the European Society for Medical Oncology and is ranked in the top 0.05% of all scholars worldwide by ScholarGPS as a Highly Ranked Scholar. Her work has been featured in The ASCO Post, Blood Cancers Today, Research Features and Open Access Government United Kingdom. She completed her postdoctoral research fellowship in the Division of Hematology/Oncology, Department of Medicine, at Dartmouth Medical School. She has an A.B. with Honors from Dartmouth College in Biochemistry and Comparative Literature, an M.S. in Genetics from the University of California, Davis, and a Ph.D. in Literature from the University of California, San Diego.